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Immune response to rabies vaccination in
pediatric transplant patients
Human rabies in the USA has decreased over the
past decades, with one to six cases reported per
year between 1993 and 2002 (1). Contrary to
popular belief, non-hematophagous bats were
the most commonly reported transmitting species
[19 of the 31 reported cases of human rabies (1)].
Rabies presents as acute progressive encephalitis
caused by one of the RNA viruses, Lyssavirus.
Especially in the case of bats as the vector, the
diagnosis of rabies may be hindered by a lack of
a clear history of exposure. A bat bite can be
painless and the incision is often <1 mm in size.
Preventing rabies associated mortality is success-
ful only with the immediate institution of pro-
phylactic measures with essentially 100%
mortality if treatment begins after symptoms
are present. Currently, only one case has been
described of a patient surviving rabies who did
not receive post-exposure prophylactic treatment
(2). Post-exposure prophylaxis remains the only
proven treatment available for preventing rabies
associated mortality (3, 4). An estimated 15 000–
40 000 people residing in the USA receive rabies
prophylaxis each year (5).
As the success of pediatric solid organ trans-
plantation grows, an increasing number of trans-
plant recipients are engaged in outdoor activities
previously limited to non-transplanted individu-
als, e.g., summer camps and sports. This expan-
sion of outdoor activities can result in exposure
to such infections as rabies. For those exposed to
rabies, a series of vaccinations is recommended
to provide protection. Currently, in solid organ
recipients, there are no data that document an
adequate immune response to the rabies vacci-
nation in this special population.
Because of the relative rarity of such exposures,
healthcare professionals who care for post-trans-
plant patients must utilize these special circum-
stances to follow the standard specific medical
interventions and determine if these interventions
are equally efficacious in the transplanted patient.
We report eight pediatric transplant (liver or
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Abstract: Children have become engaged in a wider variety of activities
as the success of solid organ transplantation has improved. These
activities can result in exposure to infectious agents for which there are
no data documenting the efficacy of standard treatment in children on
immunosuppressive therapy. This is a retrospective review of five OLT
patients and three RT patients who were potentially exposed to rabies
during camp. They completed the immunoprophylaxis treatment for
rabies exposure outlined by the CDC in the 2003 Red Book. Rabies
titers were followed for six to 12 months post-immunization. All five
OLT patients were on tacrolimus. All three RT patients were on
tacrolimus, mycophenolate mofetil, and prednisone. At the time of
exposure median age was 10.0 yr (8.4–17.3). None of the subjects
developed rabies. A positive rabies titer, indicative of successful
immunization, was present by one month in seven subjects and all
subjects by six months. Rabies vaccination in pediatric transplant
patients is safe and associated with the successful production of
antirabies titers.
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kidney) patients potentially exposed to rabies who
were treated in accordance with the 2003 Red
Book/CDC recommendation for post-exposure
vaccination. All patients received the rabies vac-
cine series and rabies immunoglobulin therapy.
We followed the patients rabies neutralizing
antibody titers to determine if these treatments
were efficacious under these special circumstances.
Methods
Patients
This is a retrospective review of five OLT patients and three
RT patients who were exposed to rabies during a week long
summer transplant camp for transplant recipients. A non-
speciated bat was identified in the cabin of the eight vaccine
recipients, of which one of the individuals had a new skin
laceration at the base of the occiput that same morning. All
campers in the cabin were vaccinated because of the painless
and tiny nature of most bat bites. The following information
was collected for each patient: the patients primary indi-
cation for transplant, type of transplant, age at transplant,
age at first rabies vaccination, time between transplant and
first rabies vaccination, any complications of the vaccina-
tion series, type of immunosuppressant medications, and
any evidence of allograft dysfunction post-immunization.
Institutional Board Review approval was obtained for this
retrospective study.
Vaccines
The most current rabies post-exposure immunization pro-
tocol was followed as outlined in the 2003 Red Book by the
CDC (6, 7). All patients received a single dose of RIG of
20 IU/kg body weight on day 0. Patients received a series of
five doses of 1.0 mL of rabies vaccine on days 0, 3, 7, 14, 28
(Table 1). The manufacture of the passive and active
immunizations was determined by availability of the
immunizations at the treating medical facility.
Serological testing
Rabies virus neutralizing antibody titers were obtained at
one, three, six, and 12 months after vaccination. Samples
were tested using the RFFIT, which is the standard type of
serological testing used by the CDC. Different laboratories
were used to measure the antibody response which resulted
in different reporting techniques. Titers >0.5 IU/mL or
‘‘Present’’ are considered indicative of an efficacious re-
sponse to the immunization series (such a response is con-
sidered to indicate adequate protection for the non-
immunosuppressed population).
Statistical analysis
Descriptive statistics including mean, median, and standard
deviation are reported. The small sample size and the het-
erogeneity of antibody titer measurements limited further
statistical comparison.
Results
The median age at the time of the rabies exposure
for the eight recipients was 10.0 yr (range 8.4–
17.3 yr). Patients were a median of 4.4 yr (range
0.9–16.1 yr) post-transplant. All were male. All
five OLT patients were on tacrolimus as the sole
immunosuppressant (goal trough 3–5 ng/mL).
Original diagnoses were biliary atresia in two
patients, acute liver failure in two patients, and
progressive familial intrahepatic cholestasis in
one patient (Table 2). None had recent compli-
cations of their transplant allograft. All three RT
patients were on tacrolimus (goal trough 4–6 ng/
mL for patients 6 and 8; goal trough 6–8 ng/mL
for patient 7), mycophenolate mofetil (500–
600 mg/m2/day divided b.i.d.), and prednisone
(0.15 mg/kg/day, maximum dose 10 mg). Origi-
nal diagnoses in the renal transplant patients
were renal cortical necrosis from sepsis, FSGS,
and obstructive uropathy from posterior urethe-
ral valves.
None of the subjects developed rabies in the
one-yr period following exposure. No patient
had any severe adverse reaction to the vaccina-
tions. No patient developed allograft rejection.
In the OLT patients, the mean titers (IU/
mL) ± s.d. at one, three, six, and 12 months
were 8.99 ± 3.22, 3.78 ± 2.13, 2.90 ± 1.19,
and 2.20 ± 1.39, respectively. The mean titers
could not be measured for the remaining patients
because the results were reported either qualita-
tively or above certain thresholds. However, after
six months of follow-up all patients demon-
strated an efficacious response to the vaccine.
Patient 4 had a liver biopsy one-month post-
vaccination for chronic elevation of liver en-
zymes at approximately 1.5· normal. The biopsy
demonstrated chronic hepatitis with mild fea-
tures suggestive of autoimmune-like changes. His
liver tests remained stable during the one-yr
follow-up period without any change in manage-
ment. Patient 7 had post-transplant recurrence of




1 OLT HyperRab RabAvert
2 OLT HyperRab RabAvert
3 OLT HyperRab RabAvert
4 OLT HyperRab RabAvert
5 OLT HyperRab RabAvert
6 LLRT BayRab Imovax
7 DRT BayRab RabAvert
8 LLRT BayRab Imovax
OLT, orthotopic liver transplant; LLRT, living related renal transplant; DRT,
deceased donor renal transplant.
aPassive Immunization: Brand name/manufacturer; Bayrab (Bayer), HyperRab
(Talecris Biotherapeutics).
bActive Immunization: Brand name/manufacture: RabAvert (Chiron Behring),
Imovax (Aventis Pasteur).
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his focal segmental glomerular sclerosis within
the first month of his transplant and predated the
rabies exposure. He initially received plasmaphe-
resis, but this was discontinued prior to his
potential rabies exposure. He had an estimated
GFR of 25–30 mL/min/1.73 m2 during the study
period.
Discussion
Rabies immunization resulted in antibody titers
above the protective cutoff in all but one patient
by one month. The results outlined in Table 2
support all subjects responded to the immuniza-
tion, with positive rabies titers by six months
post-vaccination. The administration of human
rabies immune globulin alone rarely results in
protective rabies titers (8). Therefore, the anti-
body titers seen at one month in our patients are
likely the results of an immune response to the
cell culture vaccines. Our heterogeneous study
with a limited number of subjects limits the
ability to determine if one brand of vaccine is
superior in this transplant population. Also, we
are not able to determine if there is a difference in
antibody titer response between the liver and
renal transplant patients as different reporting
mechanisms and immunosuppression regiments
were used. However, the antibody response
appears to be less than a group of 19 immuno-
competent children ages 7–10 who received the
rabies vaccine series. Their immune response
demonstrated an antibody response range of
3–33 IU/mL (mean 21 IU/mL) (9).
In renal transplant patient 7, protective titers
were not seen until six months after vaccination.
The impaired titer response to the vaccine in
patient 7 may have been secondary to his active
FSGS (nephrotic syndrome) and stage IV
chronic renal failure. The rise in titers is likely
related to clinical improvement in his nephrotic
syndrome. One surrogate marker of his nephrotic
syndrome that was consistently measured
throughout the study was his serum albumin.
At the time of his immunization his serum
albumin was 2.1 g/dL, then 2.4 g/dL at three
months, and finally 3.0 g/dL at six months.
Patient 7 was not receiving plasmapheresis at
the time of his exposure or immunizations.
Rabies vaccination in pediatric transplant
patients is safe and efficacious while receiving
low to modest amounts of immunosuppression.
Specifically, all of the subjects demonstrated a
response to the active immunization at six and
12 months. We hope this helps address one of the
potential barriers the pediatric transplant patient
may encounter when pursuing many of the
activities of non-immunosuppressed children.
This ‘‘natural experiment’’ provides important
information that this patient population should
receive the CDC recommend rabies vaccination
schedule if clinically indicated.
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Rabies titer post-immunization (IU/mL)
1 month 3 months 6 months 12 months
1 Biliary atresia OLT 17 16.1 11.69 6.23 4.23 4.09
2 Familial intrahepatic cholestasis OLT 9 2.6 4.91 2.8 2.54 1.59
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7 Focal segmental glomerulosclerosis DRT 9 0.9 £ 0.2 £ 0.2 ‡0.9 NA
8 Obstructive uropathy LRRT 9 1.1 >1.2 ‡0.8 ‡0.8 NA
OLT, orthotopic liver transplant; LLRT, living related renal transplant; DRT, deceased donor renal transplant.
Titers >0.5 IU/mL or present are considered protective.
NA, titers are not available.
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